Compare BKSY & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BKSY | ACIU |
|---|---|---|
| Founded | 2013 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 658.3M | 213.3M |
| IPO Year | N/A | 2016 |
| Metric | BKSY | ACIU |
|---|---|---|
| Price | $18.38 | $3.14 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | ★ $29.00 | $10.00 |
| AVG Volume (30 Days) | ★ 1.6M | 1.2M |
| Earning Date | 11-06-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $101,731,000.00 | $5,482,957.00 |
| Revenue This Year | $8.51 | N/A |
| Revenue Next Year | $31.31 | $738.95 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.15 | $1.43 |
| 52 Week High | $33.20 | $4.00 |
| Indicator | BKSY | ACIU |
|---|---|---|
| Relative Strength Index (RSI) | 51.31 | 55.61 |
| Support Level | $17.73 | $2.54 |
| Resistance Level | $19.80 | $2.99 |
| Average True Range (ATR) | 1.31 | 0.29 |
| MACD | 0.49 | 0.03 |
| Stochastic Oscillator | 67.95 | 50.40 |
BlackSky Technology Inc is a provider of real-time geospatial intelligence. The company delivers on-demand, high-frequency imagery, monitoring, and analytics of some of the critical and strategic locations, economic assets, and events in the world. It designs, owns, and operates one of the industry's low earth orbit (LEO) small satellite constellations, optimized to capture imagery cost-efficiently where and when its customers need it. its Spectra AI software platform processes data from BlackSky's constellation and other third-party sensors to develop the critical insights and analytics that provide its customers with the actionable intelligence. Geographically, the company operates in North America, the Middle East, Asia, and Others.
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.